Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

2021625 citationsJournal Articlebronze Open Access

Authors

Efstathios Kastritis · Utrecht University

Giovanni Palladini · Utrecht University

Monique C. Minnema · University Medical Center Utrecht

Ashutosh Wechalekar · Centre Hospitalier Universitaire de Lille

Arnaud Jaccard · Amyloidosis Foundation

Hans C. Lee · University College London

Vaishali Sanchorawala

Abstract

Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Peptidase Inhibition and Analysis Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 1, pp. 46-58

DOI: 10.1056/nejmoa2028631

Field-Weighted Citation Impact: 35.38